Clementi et al., European Journal of Pharmacology 393, 3-10, 2000.* |
SIPMA, et al., “Regulation of histimine- and UTP-induced increases in Ins(1,4,5)P3, Ins (1,3,4,5)P4 and CA2+ by cyclic AMP in DDT1 MF-2 cells,” British Journal of Pharmacology, 1995, 114, 383-390. |
Roth, et al. “Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytriptamine-6 and 5-Hydroxytryptamine-7 Receptors,” Journal of Pharmacology and Experimental Therapeutics, 1994, 268, 3, 1403-1410. |
Schwartz, et al., “A Clinician's Primer on the Circadian Clock: Its Localization, Function and Resetting,” Advances in Internal Medicine, 193, 38, 81-106. |
Leung, et al., “Characterization of putative 5-ht7 receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein,” British Journal of Pharmacology, 1996, 117, 926-930. |
Hadjuk, et al., “Novel Inhibitors of Erm Methyltransferases from NMR and Parallel Synthesis,” J. Med. Chem., 1999, 42, 3852-3859. |
Mohr, et al., “1,2,5-Triazin-2,4-diamine und -2,4,6-triamine mit, H2-antagonistischer Wirkung,” Archiv. Der Pharmazie, 319, 86, 878-885. |
Chiou, et al., “Effects of Antiglaucoma Drugs on Ocular Blood Flow in Ocular Hypertensive Rabbits,” Journal of Ocular Pharmacology, 1993, 9, 1, 13-24. |
Eglen, et al., “The 5-HT7 receptor: orphan found,” TIPS, 1997, 18, 104-107. |
Cushing, et al., “LY215840, a High-Affinity 5-HT7 Receptor Ligand, Blocks Serotonin-Induced Relaxation in Canine Coronary Artery,” Journal of Pharmacology and Experimental Therapeutics, 1996, 277, 3, 1560-1566. |
Terron, “The 5-HT7 receptor: A target for novel therapeutic avenues?”, IDRUGS, 1998, 1, 3, 302-310. |